Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ono Pharmaceutical Co. Ltd.

www.ono.co.jp

Latest From Ono Pharmaceutical Co. Ltd.

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Pipeline Watch: Phase III Starts With Fasinumab, Varlitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

What's Next On Gilead's Shopping List

With much of its cash held ex-US, Gilead is unlikely to undertake another large acquisition soon, even if there are logical reasons to bolster its NASH pipeline or try to acquire partner Galapagos. Firm is likely to follow Kite buyout with targeted cancer deals.

Business Strategies M & A

Pipeline Watch: Phase III Progress With Semaglutide, Sotagliflozin

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Ono Pharmaceutical Co. Ltd.
  • Senior Management
  • Gyo Sagara, Pres. & CEO
    Hiroshi Awata, Exec. Dir., Clinical Dev.
  • Contact Info
  • Ono Pharmaceutical Co. Ltd.
    Phone: (81) 6 6263 5670
    8-2 Kyutaromachi 1-Chome
    Chuo-ku
    Osaka, 541-8564
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register